Cuvitru

Discontinue immediately if hypersensitivity reaction occurs. Correct volume depletion prior to treatment initiation. Pre-existing renal insufficiency. Patients at risk of renal dysfunction or renal failure (eg, diabetes mellitus, >65yrs, volume depletion, sepsis, paraproteinemia, nephrotoxic agents); consider lower dose with frequent dosing. Monitor renal function, urine output, BUN, and serum creatinine prior to treatment and periodically thereafter; consider discontinuing if renal function deteriorates. Risk for thrombosis (eg, advanced age, prolonged immobilization, hypercoagulable conditions, venous or arterial thrombosis, estrogens, indwelling central venous catheters, hyperviscosity, cardiovascular risk factors); monitor and infuse lowest dose and rate practicable. Risk of hyperviscosity (eg, cryoglobulins, fasting chylomicronemia/markedly high triglycerides, monoclonal gammopathies); consider baseline assessment. Aseptic meningitis syndrome; conduct neurological exam to rule out other causes. Monitor for hemolysis if risk factors present (eg, high doses [≥2g/kg], non-O blood group); consider appropriate testing. Monitor for pulmonary reactions; if transfusion-related acute lung injury (TRALI) suspected, test for antibodies. Contains human plasma; monitor for possible viral disease and variant Creutzfeldt-Jakob disease transmission. Elderly. Pregnancy. Nursing mothers.